Literature DB >> 14663471

Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study.

B W Guess1, M C Scholz, S B Strum, R Y Lam, H J Johnson, R I Jennrich.   

Abstract

This trial investigated the tolerability and effect of modified citrus pectin (Pecta-Sol) in 13 men with prostate cancer and biochemical prostate-specific antigen (PSA) failure after localized treatment, that is, radical prostatectomy, radiation, or cryosurgery. A total of 13 men were evaluated for tolerability and 10 for efficacy. Changes in the prostate-specific antigen doubling time (PSADT) of the 10 men were the primary end point in the study. We found that the PSADT increased (P-value<0.05) in seven (70%) of 10 men after taking MCP for 12 months compared to before taking MCP. This study suggests that MCP may lengthen the PSADT in men with recurrent prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14663471     DOI： 10.1038/sj.pcan.4500679

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.554


  21 in total

1.  Microbial utilization and selectivity of pectin fractions with various structures.

Authors:  Chatchaya Onumpai; Sofia Kolida; Estelle Bonnin; Robert A Rastall
Journal:  Appl Environ Microbiol       Date:  2011-07-01       Impact factor: 4.792

Review 2.  Complementary and Integrative Medicine in Hematologic Malignancies: Questions and Challenges.

Authors:  Moshe Frenkel; Kenneth Sapire
Journal:  Curr Oncol Rep       Date:  2017-10-14       Impact factor: 5.075

3.  Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma.

Authors:  Min Kyu Kim; Chang Ohk Sung; In-Gu Do; Hye-Kyung Jeon; Tae Jong Song; Hwang Shin Park; Yoo-Young Lee; Byoung-Gie Kim; Jeong-Won Lee; Duk-Soo Bae
Journal:  Int J Clin Oncol       Date:  2011-02-16       Impact factor: 3.402

4.  A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.

Authors:  Przemyslaw Twardowski; Noriko Kanaya; Paul Frankel; Timothy Synold; Christopher Ruel; Sumanta K Pal; Maribel Junqueira; Manisha Prajapati; Tina Moore; Pamela Tryon; Shiuan Chen
Journal:  Cancer       Date:  2015-05-18       Impact factor: 6.860

Review 5.  Modified citrus pectin anti-metastatic properties: one bullet, multiple targets.

Authors:  Vladislav V Glinsky; Avraham Raz
Journal:  Carbohydr Res       Date:  2008-09-26       Impact factor: 2.104

6.  Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.

Authors:  Jessica R Newton-Northup; Marie T Dickerson; Lixin Ma; Cynthia L Besch-Williford; Susan L Deutscher
Journal:  Clin Exp Metastasis       Date:  2012-08-01       Impact factor: 5.150

7.  Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin.

Authors:  Cheppail Ramachandran; Barry J Wilk; Arland Hotchkiss; Hoa Chau; Isaac Eliaz; Steven J Melnick
Journal:  BMC Complement Altern Med       Date:  2011-08-04       Impact factor: 3.659

8.  Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice.

Authors:  Alison C MacKinnon; Xiaojun Liu; Patrick Wf Hadoke; Mark R Miller; David E Newby; Tariq Sethi
Journal:  Glycobiology       Date:  2013-02-19       Impact factor: 4.313

9.  Macropinocytosis requires Gal-3 in a subset of patient-derived glioblastoma stem cells.

Authors:  Laetitia Seguin; Soline Odouard; Francesca Corlazzoli; Sarah Al Haddad; Laurine Moindrot; Marta Calvo Tardón; Mayra Yebra; Alexey Koval; Eliana Marinari; Viviane Bes; Alexandre Guérin; Mathilde Allard; Sten Ilmjärv; Vladimir L Katanaev; Paul R Walker; Karl-Heinz Krause; Valérie Dutoit; Jann N Sarkaria; Pierre-Yves Dietrich; Érika Cosset
Journal:  Commun Biol       Date:  2021-06-10

10.  A 12 week, open label, phase I/IIa study using apatone for the treatment of prostate cancer patients who have failed standard therapy.

Authors:  Basir Tareen; Jack L Summers; James M Jamison; Deborah R Neal; Karen McGuire; Lowell Gerson; Ananias Diokno
Journal:  Int J Med Sci       Date:  2008-03-24       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.